Slayback Exclusivity On Taytulla Does Not Bar Rival ANDA Product
US-Based Player Received Approval With CGT Designation
Slayback Pharma has now launched its Merzee generic version of Allergan’s Taytulla oral contraceptive with a CGT designation, several months after Xiromed moved first.
You may also be interested in...
Milla Pharmaceuticals, part of the Alter Pharma Group, toasted three milestones as it announced approval and launch of its generic version of Pfizer’s sodium acetate 2mEq/ml injectable in the US.
The sixth annual report of the FDA’s Office of Generic Drugs covered a year dominated by the novel coronavirus pandemic – although first-time generic approvals and record levels of communication also featured prominently.
US-based player Slayback “will kick off a full commercial launch under its own label very soon” of the generic version of Allergan’s Taytulla for which it has just received approval with a competitive generic therapy designation.